393184-79-7Relevant academic research and scientific papers
A novel series of potent and selective PDE5 inhibitors with potential for high and dose-independent oral bioavailability
Allerton, Charlotte M. N.,Barber, Christopher G.,Beaumont, Kevin C.,Brown, David G.,Cole, Susan M.,Ellis, David,Lane, Charlotte A. L.,Maw, Graham N.,Mount, Natalie M.,Rawson, David J.,Robinson, Colin M.,Street, Stephen D. A.,Summerhill, Nicholas W.
, p. 3581 - 3594 (2007/10/03)
Sildenafil (5-[2-ethoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]-1-methyl- 3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one), a potent and selective phosphodiesterase type 5 (PDE5) inhibitor, provided the first oral treatment for male erectile dy
Pharmaceutically active compounds
-
, (2008/06/13)
Compound of general formula I: wherein R1, R2, R3, R4, X, Y and R5 have the meanings given herein which are useful in the curative and prophylactic treatment of a medical condition for which inhibitio
Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof
-
Page 19, (2010/01/31)
A process is provided for the preparation of compounds of formula (I) herein comprising reacting a compound of formula (II), (III), (IV) or (V) in the presence of-OR3 and a hydroxide trapping agent or in the case of compounds of formula (IV) reacting in the presence of an auxiliary base and a hydroxide trapping agent (i.e.-OR3 is substituted by the auxiliary base), wherein X is a leaving group and R1 to R4 are as defined.
